3-deazaadenosine prevents atherosclerosis and graft vasculopathy

Use of 3-deazaadenosine and analogs thereof for the manufacture of a medicament for the prevention and/or treatment of diseases associated with expression of adhesion molecules ICAM-1 and VCAM-1 in endothelial cells.

Use according to any one of the preceding claims for reducing rejection of transplanted organs.

Use according to any one of the preceding claims for the manufacture of a medicament for the prevention and/or treatment of transplant vasculopathy.

Use according to any one of the preceding claims for the manufacture of a medicament for the prevention of in-stent restenosis.

Use according to any one of the preceding claims for the manufacture of a medicament for reducing the level of homocysteine.

Use according to any one of the preceding claims in combination with an immunosuppressive medicament.

Use according to any one of the preceding claims in combination with a cholesterol-reducing agent.

Use according to any one of the preceding claims wherein the medicament is orally administered.

Use according to any one of the preceding claims wherein the dose is in the range of from 0.1 to 500 mg/kg body weight per day.

Method of treating or preventing vascular diseases or graft rejection comprising administering to a subject in need thereof an efficient amount of 3-deazaadenosine or an analog thereof.

Method of treating or preventing diseases associated with expression of adhesion molecules ICAM-1 and VCAM-1 in endothelial cells comprising administering to a subject in need thereof an efficient amount of 3-deazaadenosine or an analog thereof.